Dymista® - twice as effective as monotherapy
Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
The combination spray containing azelastine (AZ) and fluticasone (FP), Dymista®, has been shown to be twice as effective as fluticasone propionate or azelastine alone at treating the entire rhinitis symptom spectrum:1,2
In a randomized, double-blind, placebo-controlled, 2-week trial involving 779 patients with moderate-to-severe seasonal allergic rhinitis, Dymista® (MP29-02) administered as one spray to each nostril twice-daily provided greater nasal and ocular symptom improvement than azelastine (AZ) or fluticasone propionate (FP) administered alone (one spray to each nostril twice-daily).1
Click below to hear what two experts have to say about the effectiveness of Dymista® on the full spectrum of allergic rhinitis symptoms
Further Your Understanding
Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.
Impact of Rhinitis
- Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasonepropionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy AsthmaProc. 2012; 33: 324-332.
- Carr W, Bernstein J, Lieberman P, el al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin lmmonul. 2012; 129: 1282-1289.